Role of the Pharmacist in Detection of Drug Interactions Before Antitumor Treatment Initiation

NCT04142567 | Completed

• 2 other identifiers: APHP1900912018-A03512-53
• Study Type: observational
• Target: 440
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this observational study is to evaluate the benefits of a pharmacist integration in an oncology ambulatory center, to prevent drug related problems (in particular drug drug interactions) at antitumor treatment initiation. The hypothesis of this work is that a drug drug interaction will be observed in 30% of cancer patients and will have a major clinical impact in 1% of the cases. The primary endpoint is the prevalence of pharmacist interventions among patients who are going to receive an oral targeted therapy or cancer chemotherapy or immunotherapy

Conditions

Neoplasm

Keywords

Drug drug interactions; Pharmacist interventions; Cancer patients; Out patient setting

Outcome Measures

Primary Outcomes (1)

• Prevalence of Pharmacist intervention

  Percentage of patients whom antitumora treatment or usual treatment has been changed by the pharmacist intervention

  up to 1 week from date of inclusion

Secondary Outcomes (7)

• Detection of Drug -drug interactions

  up to 1 week from date of inclusion

• Clinical gradation of drug drug interactions

  One year

• Cost of the pharmacist intervention by avoided clinical consequence

  One year

• Potential cost of the avoided clinical consequences

  One year

• Adherence evaluation with oral cancer targeted therapy by therapeutic drug monitoring

  day 15, 30 and 6 months after oral therapy initiation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Cancer patients in outpatient setting, treated in two Paris hospitals

You may qualify if:

• legal age patients
• Affiliated to social security or with another insurance system
• with a solid tumor
• who are going to receive an antitumor treatment (chemotherapy, immunotherapy or oral targeted therapy)

You may not qualify if:

• pregnant women
• minor patient

Sponsors & Collaborators

• Assistance Publique - Hôpitaux de Paris: lead
• URC-CIC Paris Descartes Necker Cochin: collaborator

Study Sites (1)

APHP -Cochin Hospital and Georges Pompidou European Hospital

Paris, 75014, France

Location

Related Publications (7)

• Thomas-Schoemann A, Blanchet B, Bardin C, Noe G, Boudou-Rouquette P, Vidal M, Goldwasser F. Drug interactions with solid tumour-targeted therapies. Crit Rev Oncol Hematol. 2014 Jan;89(1):179-96. doi: 10.1016/j.critrevonc.2013.08.007. Epub 2013 Aug 28.

  PMID: 24041628 BACKGROUND

• P. Boudou Rouquette, A. Thomas-Schoemann, A. Chahwakilian et al., Clinical benefit of a one-day multidisciplinary work-up for risk assessment in unfit cancer patients. ESMO congress, abstract 1558; Amsterdam 2013

  BACKGROUND

• Bonnet C, Boudou-Rouquette P, Azoulay-Rutman E, Huillard O, Golmard JL, Carton E, Noe G, Vidal M, Orvoen G, Chah Wakilian A, Villeminey C, Blanchet B, Alexandre J, Goldwasser F, Thomas-Schoemann A. Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France. Cancer Chemother Pharmacol. 2017 May;79(5):1051-1055. doi: 10.1007/s00280-017-3291-z. Epub 2017 Mar 30.

  PMID: 28361167 BACKGROUND

• Lees J, Chan A. Polypharmacy in elderly patients with cancer: clinical implications and management. Lancet Oncol. 2011 Dec;12(13):1249-57. doi: 10.1016/S1470-2045(11)70040-7. Epub 2011 Jul 6.

  PMID: 21741307 BACKGROUND

• Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007 Apr 18;99(8):592-600. doi: 10.1093/jnci/djk130.

  PMID: 17440160 BACKGROUND

• Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009 Jan-Feb;59(1):56-66. doi: 10.3322/caac.20004.

  PMID: 19147869 BACKGROUND

• Giraud JS, Korb-Savoldelli V, Perrin G, Jouinot A, Sabatier B, Batista R, Ribault M, De Percin S, Villeminey C, Videau M, Blanchet B, Goldwasser F, Degrassat-Theas A, Thomas-Schoemann A. Clinical and economic impact of pharmacist interventions to identify drug-related problems in multidisciplinary cancer care: a prospective trial. Oncologist. 2025 Aug 4;30(8):oyae213. doi: 10.1093/oncolo/oyae213.

  PMID: 39403043 RESULT

MeSH Terms

Conditions

Neoplasms

Study Officials

• Audrey Thomas-Schoemann, PharmD, PhD

  Assistance Publique - Hôpitaux de Paris

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 4, 2019
• First Posted: October 29, 2019
• Study Start: February 11, 2020
• Primary Completion: April 23, 2021
• Study Completion: October 22, 2021
• Last Updated: March 27, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)